ReviewNature reviews. Clinical oncology2022
COVID-19 vaccines in patients with cancer: immunogenicity, efficacy and safety.
Review in Nature reviews. Clinical oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 128 papers, 7 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
128 citing papers in PubMed, 7 syntheses or guidelines pooled it, 207 citations in OpenAlex.
- Minimum Data Set and Metadata for Active Vaccine Safety Surveillance: Systematic Review.JMIR public health and surveillance · 2025Pooled it
- Pooled it
- AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants.European journal of cancer (Oxford, England : 1990) · 2023Guideline
- COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis.Journal for immunotherapy of cancer · 2023Pooled it
- Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2022Pooled it
- Immunogenicity of COVID-19 vaccines in patients with diabetes mellitus: A systematic review.Frontiers in immunology · 2022Pooled it
- Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis.Frontiers in oncology · 2022Pooled it
- COVID-19 vaccination around immune checkpoint inhibitor start and survival in a nationwide cohort of patients with cancer.Nature medicine · 2026Article
- Impact of Prior mRNA COVID-19 Vaccination on PFS2 in NSCLC Patients Receiving Second-Line Immune Checkpoint Inhibitors: A Real-World Analysis.Journal of clinical medicine · 2026Article
- Vaccination in Oncology Patients: Evidence, Clinical Challenges, and Future Directions.Vaccines · 2026Review
- A multicenter, observational study to evaluate the safety of restarting antitumor therapy recovered from COVID-19.Future oncology (London, England) · 2026Observational
- Possible role of pre-vaccination T-lymphocyte subpopulations in the antibody response to COVID-19 vaccines in children undergoing chemotherapy.Frontiers in immunology · 2026Article
- Cancer burden and the contributions of risk factors in China: A systematic analysis for the Global Burden of Disease Study 2021.Chinese medical journal · 2025Article
- Neutralizing antibody responses to the primary series of a COVID-19 mRNA vaccine in the cancer cohort under active treatment.Human vaccines & immunotherapeutics · 2025Article
- Review
- Chemotherapy drugs do not affect the production of hepatitis B surface antibodies: A case report.Oncology letters · 2025Article
- Clinical Impacts of Immunogenicity in Approved Antibody Drugs in Japan: A Quantitative Evaluation of Pharmacokinetics, Efficacy, and Safety Outcomes.The AAPS journal · 2025Article
- Comprehensive analysis of cancer and non-cancer mortality in patients with bone metastases: A population-based study.Journal of bone oncology · 2025Article
- Immunogenicity of SARS-CoV-2 mRNA Vaccine in Breast Cancer Patients Undergoing Active Treatment: A Prospective Observational Study.Pathogens (Basel, Switzerland) · 2025Observational
- Humoral and Cellular Immune Responses to SARS-CoV-2 in Participants with Head and Neck Cancer.Viruses · 2025Article
68 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 7 institutions in 3 countries.
Funding
Abstract
Patients with cancer have a higher risk of severe coronavirus disease (COVID-19) and associated mortality than the general population. Owing to this increased risk, patients with cancer have been prioritized for COVID-19 vaccination globally, for both primary and booster vaccinations. However, given that these patients were not included in the pivotal clinical trials, considerable uncertainty remains regarding vaccine efficacy, and the extent of humoral and cellular immune responses in these patients, as well as the risks of vaccine-related adverse events. In this Review, we summarize the current knowledge generated in studies conducted since COVID-19 vaccines first became available. We also highlight critical points that might affect vaccine efficacy in patients with cancer in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.